Sign up to view this video Join Now Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Decentralized by Design: Operationalizing Hybrid Rare Disease Trials Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials Innovating Clinical Outcome Assessments in Rare Disease Trials: Integrating Patient-Centered Measures and Digital Health Technologies
Sign up to view this video Join Now Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Decentralized by Design: Operationalizing Hybrid Rare Disease Trials Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials Innovating Clinical Outcome Assessments in Rare Disease Trials: Integrating Patient-Centered Measures and Digital Health Technologies
